Skip to main content

Table 1 Demographic characteristics, disease characteristics, symptoms, and manometry in the study population (n = 22)

From: The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial

Variable Value
Age (years) 52. 5 ± 11.9
Sex (female/male) 19/3
Duration of disease (years)a 8.7 ± 6.7
Diffuse SSc (n (%)) 16 (72.7)
Pulmonary fibrosisb 15 (68.1)
Digital ulcersc 10 (45.5)
Anti-Scl 70 (%) 9 (41 %)
ANA (%) 19 (86.4 %)
ACA (%) 2 (9.1 %)
CPK (> × 2 normal values) (%) 2 (9.1 %)d
Supra-aortic coronal diameters (cm) 12.4 ± 5.3
Infra-aortic coronal diameters (cm) 22.5 ± 11.1
Frequency of symptoms (%)
 -dysphagia 12 (54.5)
 -heartburn 20 (91.0)
 -regurgitation 19 (86.0)
 -chest pain 8 (36.4)
severity of symptoms (0–100)
 -dysphagia 25.8 ± 30.7
 -heartburn 27.1 ± 24.0
 -regurgitation 39.3 ± 29.8
 -chest pain 10.4 ± 2.1
amplitude of distal contractions (mmHg) 16.6 ± 9.6
duration of distal contractions (cm) 3.7 ± 2.4
velocity of distal contractions (cm/sec) 2.6 ± 1.9
LES resting pressure (mmHg) 7.7 ± 3.9
LES residual pressure (mmHg) 2.9 ± 1.9
IRP (mmHg) 3.1 ± 2.3
  1. SSc systemic sclerosis, ANA antinuclear antibody, ACA anti-centromere antibody, LES lower esophageal sphincter, IRP integrated relaxation pressure, HRCT, High resolution computed tomography, CPK, creatinophosphokinase, anti-Scl, anti-topoisomerase I
  2. aDisease duration was from first non-Raunaud’s symptom
  3. bPresence of interstitial lung disease was determined after evaluation of HRCT
  4. cFive out of these ten patients had active digital ulcers at the time of the manometry
  5. dNone of the patients had clinical signs of myositis or skeletal myopathy